Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, achieved a significant milestone related to its lead investigational product early this year.
On Jan.22, 2024, the company announced that the FDA has accepted its Biologics License Application for Obecabtagene autoleucel for patients with relapsed/refractory Adult B-Cell Acute Lymphoblastic Leukemia, with a decision date set for November 16, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com